Cell Signaling Technology Logo - Extra Large
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TSLPR/CRLF2 (F3K9G) Rabbit mAb #19582

Filter:
  • WB
  • IP
  • F

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 60
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Flow Cytometry (Fixed/Permeabilized) 1:200 - 1:800
    Flow Cytometry (Live) 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TSLPR/CRLF2 (F3K9G) Rabbit mAb recognizes endogenous levels of total TSLPR/CRLF2 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human TSLPR/CRLF2 protein.

    Background

    Thymic stromal lymphopoietin (TSLP) is a cytokine produced by epithelial cells at barrier surfaces and granulocytes (1). TSLP acts on dendritic cells, lymphocytes, and granulocytes by binding to a heterodimer composed of TSLPR (TSLP receptor; also known as cytokine receptor-like factor 2 or CRLF2) and IL-7Rα (2-5). Activation of this heterodimer further activates the Jak/Stat signaling pathway and stimulates cellular proliferation (6-8). TSLPR/CRLF2 overexpression is linked to leukemia, where it is identified in 5-15% of all cases of B-cell acute lymphoblastic leukemia (B-ALL) and is the most common hallmark of the Philadelphia chromosome (Ph)-like B-ALL subtype (8-11). This overexpression is associated with poor clinical outcome, and TSLPR/CRLF2 is increasingly being studied as a target for B-ALL immunotherapies (12,13).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.